AJP - Lung Fuel your research with LabChart
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 QUICK SEARCH:   [advanced]


     


Am J Physiol Lung Cell Mol Physiol (July 25, 2003). doi:10.1152/ajplung.00185.2003
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
285/5/L1116    most recent
00185.2003v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Audi, S. H.
Right arrow Articles by Merker, M. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Audi, S. H.
Right arrow Articles by Merker, M. P.
Submitted on June 12, 2003
Accepted on July 21, 2003

DUROQUINONE REDUCTION DURING PASSAGE THROUGH THE PULMONARY CIRCULATION

Said H. Audi1*, Robert D. Bongard2, Christopher A. Dawson3, David Siegel4, David L. Roerig5, and Marilyn P. Merker5

1 Department of Biomedical Engineering, Marquette University, Milwaukee, WI, USA; Department of Pulmonary and Critical Care Medicine, Medical College of Wisconsin, Milwaukee, WI, USA
2 Department of Physiology, Medical College of Wisconsin, Milwaukee, WI, USA
3 Department of Biomedical Engineering, Marquette University, Milwaukee, WI, USA; Department of Physiology, Medical College of Wisconsin, Milwaukee, WI, USA; Research Service, Zablocki VA Medical Center, Milwaukee, WI, USA
4 School of Pharmacy, University of Colorado Health Sciences Center, Denver, CO, USA
5 Department of Anesthesiology, Medical College of Wisconsin, Milwaukee, WI, USA; Department of Pharmacology/Toxicology, Medical College of Wisconsin, Milwaukee, WI, USA; Research Service, Zablocki VA Medical Center, Milwaukee, WI, USA

* To whom correspondence should be addressed. E-mail: audis{at}mu.edu.

The lungs have a substantial capacity for influencing the redox status of redox active plasma constituents. The objective of this study was to examine some aspects of the kinetics and mechanisms that can determine the pulmonary disposition of redox active compounds during passage through the pulmonary circulation. Experiments were carried out on lungs from rats and mice using 2,3,5,6-tetramethyl-1,4-benzoquinone (duroquinone, DQ) as a model amphipathic quinone reductase substrate. The primary measurements were of DQ and durohydroquinone (DQH2) concentrations in the lung venous effluent after injecting, or while infusing, DQ or DQH2 into the pulmonary arterial inflow. The maximum net rates of DQ reduction to DQH2 in the rat and mouse lungs were about 4.9 and 2.5 µmole/min/gram dry lung wt, respectively. The net reduction DQ rate was apparently the result of freely permeating access of DQ and DQH2 to tissue sites of redox reactions, dominated by dicumarol sensitive DQ reduction to DQH2 and cyanide sensitive DQH2 re-oxidation back to DQ. The dicumarol sensitivity along with immuno-detectable expression of NAD(P)H: quinone oxidoreductase 1 (NQO1) in the rat lung tissue suggest that the dominant site of DQ reduction is cytoplasmic NQO1. The effect of cyanide on DQH2 oxidation suggests that the dominant site of oxidation is complex III of the mitochondrial electron transport chain. Envisioning DQ as a model compound for examining the disposition of amphipathic NQO1 substrates in the lungs, the results are consistent with a role for lung NQO1 in determining the redox status of such compounds in the circulation. In the case of DQ, the effect is conversion of a redox cycling, oxygen activating, quinone into its stable hydroquinone during passage through the pulmonary circulation.




This article has been cited by other articles:


Home page
J. Appl. Physiol.Home page
S. H. Audi, M. P. Merker, G. S. Krenz, T. Ahuja, D. L. Roerig, and R. D. Bongard
Coenzyme Q1 redox metabolism during passage through the rat pulmonary circulation and the effect of hyperoxia
J Appl Physiol, October 1, 2008; 105(4): 1114 - 1126.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
M. P. Merker, S. H. Audi, B. J. Lindemer, G. S. Krenz, and R. D. Bongard
Role of mitochondrial electron transport complex I in coenzyme Q1 reduction by intact pulmonary arterial endothelial cells and the effect of hyperoxia
Am J Physiol Lung Cell Mol Physiol, September 1, 2007; 293(3): L809 - L819.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
M. P. Merker, S. H. Audi, R. D. Bongard, B. J. Lindemer, and G. S. Krenz
Influence of pulmonary arterial endothelial cells on quinone redox status: effect of hyperoxia-induced NAD(P)H:quinone oxidoreductase 1
Am J Physiol Lung Cell Mol Physiol, March 1, 2006; 290(3): L607 - L619.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
S. H. Audi, R. D. Bongard, G. S. Krenz, D. A. Rickaby, S. T. Haworth, J. Eisenhauer, D. L. Roerig, and M. P. Merker
Effect of chronic hyperoxic exposure on duroquinone reduction in adult rat lungs
Am J Physiol Lung Cell Mol Physiol, November 1, 2005; 289(5): L788 - L797.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Visit Other APS Journals Online
Copyright © 2003 by the American Physiological Society.